Mizuho Securities analyst Vamil Divan maintained a Buy rating on Pfizer (PFE) today and set a price target of $42.00. The company’s shares closed last Tuesday at $40.13.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.1% and a 49.1% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $42.50.
See today’s analyst top recommended stocks >>
Based on Pfizer’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.95 billion and net profit of $594 million. In comparison, last year the company earned revenue of $2.11 billion and had a GAAP net loss of $336 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
